Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Argus Health
Chubb
Boehringer Ingelheim
UBS
Teva
Merck

Generated: September 16, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR PRASUGREL HYDROCHLORIDE

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Clinical Trials for Prasugrel Hydrochloride

Trial ID Title Status Sponsor Phase Summary
NCT00059215 A Trial of CS-747 (Prasugrel) Compared With Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention (PCI) Completed Eli Lilly and Company Phase 2 The purpose of this study is to evaluate the effects of a drug known as CS-747 (also known as prasugrel) on subjects having a procedure called a percutaneous coronary intervention (also referred to as PCI) in which a doctor will attempt to open a blocked vessel (or vessels) in the heart using a catheter (a long thin tube) that has a small balloon on the end. In many cases, patients who have this procedure receive a stent, a small wire spring that helps keep the vessel open.
NCT00097591 A Comparison of Prasugrel (CS-747) and Clopidogrel in Acute Coronary Syndrome Subjects Who Are to Undergo Percutaneous Coronary Intervention Completed Daiichi Sankyo Inc. Phase 3 The sponsors of this investigational drug are developing prasugrel (also known as CS-747) as a possible treatment for patients with acute coronary syndrome (heart attack or chest pain) who need, or are expected to need, a percutaneous coronary intervention (PCI; also called a balloon angioplasty). Prasugrel was compared with Clopidogrel to determine which drug is better at reducing deaths, future heart attacks, or stroke.
NCT00097591 A Comparison of Prasugrel (CS-747) and Clopidogrel in Acute Coronary Syndrome Subjects Who Are to Undergo Percutaneous Coronary Intervention Completed Eli Lilly and Company Phase 3 The sponsors of this investigational drug are developing prasugrel (also known as CS-747) as a possible treatment for patients with acute coronary syndrome (heart attack or chest pain) who need, or are expected to need, a percutaneous coronary intervention (PCI; also called a balloon angioplasty). Prasugrel was compared with Clopidogrel to determine which drug is better at reducing deaths, future heart attacks, or stroke.
NCT00356135 Effect of Prasugrel on Platelets After One Week in Patients Already Taking Clopidogrel After a Cardiac Event Completed Daiichi Sankyo Inc. Phase 2 This study will compare the effect of a prasugrel 10-mg maintenance dose with a clopidogrel 75-mg maintenance dose on platelet activity, approximately 1 week after the first dose of study drug, in subjects who have been taking clopidogrel 75 mg daily following a percutaneous coronary intervention (PCI) with placement of a stent, performed to treat acute coronary syndrome (ACS).
NCT00356135 Effect of Prasugrel on Platelets After One Week in Patients Already Taking Clopidogrel After a Cardiac Event Completed Eli Lilly and Company Phase 2 This study will compare the effect of a prasugrel 10-mg maintenance dose with a clopidogrel 75-mg maintenance dose on platelet activity, approximately 1 week after the first dose of study drug, in subjects who have been taking clopidogrel 75 mg daily following a percutaneous coronary intervention (PCI) with placement of a stent, performed to treat acute coronary syndrome (ACS).
>Trial ID >Title >Status >Phase >Summary

Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Prasugrel Hydrochloride

Condition Name

Condition Name for Prasugrel Hydrochloride
Intervention Trials
Coronary Artery Disease 50
Acute Coronary Syndrome 37
Myocardial Infarction 14
Acute Coronary Syndromes 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Prasugrel Hydrochloride
Intervention Trials
Coronary Artery Disease 59
Myocardial Ischemia 58
Coronary Disease 55
Acute Coronary Syndrome 53
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Prasugrel Hydrochloride

Trials by Country

Trials by Country for Prasugrel Hydrochloride
Location Trials
United States 394
United Kingdom 37
Italy 27
Germany 24
Canada 23
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Prasugrel Hydrochloride
Location Trials
Florida 32
Texas 16
Massachusetts 16
Ohio 15
California 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Prasugrel Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Prasugrel Hydrochloride
Clinical Trial Phase Trials
Phase 4 94
Phase 3 41
Phase 2/Phase 3 3
[disabled in preview] 32
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Prasugrel Hydrochloride
Clinical Trial Phase Trials
Completed 88
Recruiting 35
Not yet recruiting 22
[disabled in preview] 33
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Prasugrel Hydrochloride

Sponsor Name

Sponsor Name for Prasugrel Hydrochloride
Sponsor Trials
Eli Lilly and Company 26
Daiichi Sankyo Inc. 18
University of Patras 13
[disabled in preview] 20
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Prasugrel Hydrochloride
Sponsor Trials
Other 215
Industry 96
U.S. Fed 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
Express Scripts
QuintilesIMS
Medtronic
Farmers Insurance
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.